Indivior Pharmaceuticals Inc Revenue Growth Rates (INDV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Indivior Pharmaceuticals Inc   (NASDAQ: INDV)
 

INDV's Revenue Growth by Quarter and Year

Indivior Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/INDV/growth
https://api.csimarket.com/api/v1/companies/INDV/fundamentals
https://api.csimarket.com/api/v1/companies/INDV/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
INDV Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 356.00
2nd Quarter June 343.00
1st Quarter March 317.00
FY 1,016.00





INDV Revenue third quarter 2026 Y/Y Growth Comment
Indivior Pharmaceuticals Inc achieved in the third quarter 2026, above Company average Revenue increase of 13.74% year on year, to $ 356.00 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Indivior Pharmaceuticals Inc ' s Revenue growth of 13.74% ranks overall at the positon no. 2616 in the third quarter 2026.


INDV Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 13.74 %
2nd Quarter June 13.58 %
1st Quarter March 19.62 %
FY   -

Financial Statements
Indivior Pharmaceuticals Inc 's third quarter 2026 Revenue $ 356.00 millions INDV's Income Statement
Indivior Pharmaceuticals Inc 's third quarter 2025 Revenue $ 313.00 millions Quarterly INDV's Income Statement


INDV Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.79 %
2nd Quarter June 8.2 %
1st Quarter March -11.94 %
FY (Year on Year)   -


Back to INDV Growth rate Comparisons >> Back to INDV Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #375
Overall #2616

Revenue Y/Y Growth Statistics
High Average Low
4.29 % -27.16 % -40.33 %
(Sep 30 2025)   (Dec 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #375
Overall #2616
Revenue Y/Y Growth Statistics
High Average Low
4.29 % -27.16 % -40.33 %
(Sep 30 2025)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Indivior Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
286.97 % 17.21 % -77.69 %
(Dec 31 2024)  


INDV's III. Quarter Q/Q Revenue Comment
Indivior Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue growth of 3.79% quarter on quarter, to $ 356.00 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 3.64% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Indivior Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 919.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #139
Overall #919
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #139
Overall #919
Revenue Q/Q Growth Statistics
High Average Low
286.97 % 17.21 % -77.69 %
(Dec 31 2024)  


INDV's III. Quarter Q/Q Revenue Comment
Indivior Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue growth of 3.79% quarter on quarter, to $ 356.00 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 3.64% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Indivior Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 919.


Indivior Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 1,376.00
Y / Y Revenue Growth (TTM) -33.46 %
Year on Year Revenue Growth Overall Ranking # 2157
Seqeuential Revenue Change (TTM) 3.23 %
Seq. Revenue Growth (TTM) Overall Ranking # 2616


Cumulative Revenue growth Comment
Indivior Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Indivior Pharmaceuticals Inc 's annual Revenue improvement would be -33.46% year on year to $1,376 millions.

In the Healthcare sector 320 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2019 to 2157.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 321
Overall # 2157

Revenue TTM Y/Y Growth Statistics
High Average Low
4.29 %
 -27.16 %
-40.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 375
S&P 500 # 2616
Cumulative Revenue growth Comment
Indivior Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Indivior Pharmaceuticals Inc 's annual Revenue drop would be -33.46% year on year to $1,376 millions.

In the Healthcare sector 320 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2019 to 2157.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 321
Overall # 2157

Revenue TTM Y/Y Growth Statistics
High Average Low
4.29 %
-27.16 %
-40.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 375
S&P 500 # 2616




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INDV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Harvard Apparatus Regenerative Technology Inc 17.89%$ 17.886 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions


About Indivior Pharmaceuticals Inc Revenue Growth Rates (INDV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Indivior Pharmaceuticals Inc (CIK 1625297).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-068013
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Indivior Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.